Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Septerna, Inc.NASDAQ: SEPN

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development grows, but more slowly than its trailing trend

Q3 FY2026 research & development of $36.56M rose 50.7% year over year, behind the +56.0% change in trailing-twelve-month research & development. Sequentially, it rose 4.1% from the prior quarter.

Context

  • Research & development amounted to 212.4% of revenue in FY2025, down 5865.5 pp from a year earlier.
  • Research & development increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly growth recovers from +50.7% toward the trailing-twelve-month pace of +56.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$36.56M+4.1% QoQ
Last fiscal yearDec 2025
$97.58M+49.4% YoY
LTMSep 2026
$132.66M+56.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.7%——
1 year+49.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
97.58M USD
Year-over-year change
+49.4%
2-year CAGR
+64.7%

Research & Development vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 research & development of $132.66M is the 2nd highest of the 7 companies compared; the peer median is $105.19M.
  • Its year-over-year change of +56.0% is the 3rd highest of 6, against a peer median of +35.7%.
  • Research & development amounts to 137.8% of revenue for SEPN, versus a peer median of 319.0%.
SEPN Competitors Peer median
Research & Development for SEPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$294.44M +79.9%+83.9%—
SEPNSepterna, Inc.LTM Sep 2026$132.66M +56.0%—137.8%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$114.57M +28.4%+7.1%572.9%
KLRAKailera Therapeutics, Inc.FY2025$109.11M ———
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$101.27M +35.7%+54.7%—
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M -55.0%-0.4%—
VTVTvTv Therapeutics Inc.LTM Mar 2026$24.01M +104.7%+13.1%65.2%
Peer median (excluding SEPN) $105.19M+35.7%+13.1%319.0%

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue151K1.08M45.95M
Cost of Revenue000
Gross Profit151K1.08M45.95M
Gross Margin100.0%100.0%100.0%
Research & Development35.98M65.34M97.58M
Selling, General & Admin9.72M16.56M29.16M
Operating Expenses(1.92M)81.9M126.75M
Depreciation & Amortization848K1.4M1.6M
EBITDA(44.7M)(70.9M)(47.26M)
EBITDA Margin-29604.0%-6594.9%-102.9%
Operating Income2.08M(80.82M)(80.8M)
Operating Margin1374.2%-7518.4%-175.8%
Interest Income2.79M8.62M19.53M
Interest Expense000
Other Income / Expenses2.8M8.53M31.93M
Income Before Tax4.87M(72.3M)(48.87M)
Pre-Tax Margin3225.8%-6725.2%-106.3%
Income Tax Expense691K(498K)12K
Net Income4.18M(71.8M)(48.88M)
Net Margin2768.2%-6678.9%-106.4%
EPS (Basic)0.03(1.93)(1.10)
EPS (Diluted)0.03(1.93)(1.10)
Weighted Avg Shares19.5M37.19M44.26M
Weighted Avg Shares (Diluted)19.5M37.19M44.26M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.